Takeda Pharmaceutical Company Limited Website

Takeda Pharmaceutical Company Limited

TSE-4502

Income Statement
Mar '15
Mar '16
Mar '17
Mar '18
Mar '19
Mar '20
Mar '21
Mar '22
Mar '23
Mar '24
LTM

Total Revenues

3,291,188

3,197,812

3,569,006

4,027,478

4,263,762

4,413,134

Total Revenues % Chg.

56.9%

-2.8%

11.6%

12.8%

5.9%

7.3%

Cost of Goods Sold, Total

1,120,146

1,013,655

1,127,308

1,253,163

1,431,505

1,497,345

Gross Profit

2,171,042

2,184,157

2,441,698

2,774,315

2,832,257

2,915,789

Selling General & Admin Expenses, Total

964,268

875,514

886,327

997,234

1,053,819

1,075,736

R&D Expenses

492,088

455,765

526,087

633,325

728,617

734,339

Amortization of Goodwill and Intangible Assets

407,343

405,229

418,789

485,102

521,525

536,762

Other Operating Expenses

10,663

23,602

10,433

38,987

35,059

59,787

Other Operating Expenses, Total

1,874,362

1,760,110

1,841,636

2,154,648

2,339,020

2,406,624

Operating Income

296,680

424,047

600,062

619,667

493,237

509,165

Interest Expense, Total

-149,010

-130,806

-122,432

-116,973

-115,392

-115,508

Interest And Investment Income

12,646

2,153

4,763

5,781

11,628

15,850

Net Interest Expenses

-136,364

-128,653

-117,669

-111,192

-103,764

-99,658

Income (Loss) On Equity Invest.

-23,987

76

-15,367

-8,630

6,473

6,179

Currency Exchange Gains (Loss)

10,979

-15,575

-3,903

-9,729

-13,612

-13,612

Other Non Operating Income (Expenses)

-10,631

1,118

-26,119

3,975

-31,520

-31,519

EBT, Excl. Unusual Items

136,677

281,013

437,004

494,091

350,814

370,555

Restructuring Charges

-181,831

-115,875

-83,836

-59,234

-81,358

-81,358

Merger & Related Restructuring Charges

—

—

—

—

—

—

—

—

—

Gain (Loss) On Sale Of Investments

—

—

—

8,482

22,416

—

—

Gain (Loss) On Sale Of Assets

19,871

235,117

8,164

8,901

7,975

7,975

Asset Writedown

-60,974

-17,521

-54,421

-62,484

-139,809

-157,980

Insurance Settlements

—

—

—

8,279

—

—

—

—

—

Legal Settlements

—

—

—

—

—

-17,401

-20,319

-16,455

-45,212

-45,212

Other Unusual Items

17,224

902

7,497

-12,145

-39,619

-39,619

EBT, Incl. Unusual Items

-60,754

366,235

302,571

375,090

52,791

54,361

Income Tax Expense

-105,044

-9,936

72,405

58,052

-91,406

-95,729

Earnings From Continuing Operations

44,290

376,171

230,166

317,038

144,197

150,090

Minority Interest

-49

-166

-107

-21

-130

-170

Net Income

44,241

376,005

230,059

317,017

144,067

149,920

Net Income to Common Incl Extra Items

44,241

376,005

230,059

317,017

144,067

149,920

Net Income to Common Excl. Extra Items

44,241

376,005

230,059

317,017

144,067

149,920

Total Shares Outstanding

1,557.8

1,563.4

1,550.4

1,554.5

1,569

1,569.1

Weighted Avg. Shares Outstanding

1,557.2

1,562

1,563.5

1,551.8

1,564.5

1,568.1

Weighted Avg. Shares Outstanding Dil

1,566.2

1,573.5

1,577.2

1,569.9

1,580.3

1,586.3

EPS

28.4

240.7

147.1

204.3

92.1

95.6

EPS Diluted

28.3

239

145.9

201.9

91.2

94.5

EBITDA

880,329

983,718

1,183,213

1,210,650

1,137,698

1,174,345

Effective Tax Rate

172.9%

-2.7%

23.9%

15.5%

-173.1%

-176.1%